HC Wainwright Reaffirms Buy Rating for Cibus (NASDAQ:CBUS)

HC Wainwright reaffirmed their buy rating on shares of Cibus (NASDAQ:CBUS) in a report published on Monday,Benzinga reports. The brokerage currently has a $25.00 price objective on the stock. HC Wainwright also issued estimates for Cibus’ Q4 2024 earnings at ($1.00) EPS, FY2025 earnings at ($3.38) EPS, FY2026 earnings at ($3.16) EPS, FY2027 earnings at ($2.39) EPS and FY2028 earnings at ($1.05) EPS.

Other equities analysts also recently issued research reports about the company. Canaccord Genuity Group restated a “buy” rating and issued a $20.00 price objective on shares of Cibus in a report on Tuesday, October 22nd. Canaccord Genuity Group upgraded Cibus to a “strong-buy” rating in a report on Friday, July 19th. Finally, Alliance Global Partners lowered their price target on Cibus from $25.00 to $23.50 and set a “buy” rating on the stock in a report on Tuesday, September 24th.

Cibus Price Performance

NASDAQ CBUS opened at $4.78 on Monday. The company has a 50 day simple moving average of $4.03 and a 200-day simple moving average of $8.58. The firm has a market capitalization of $126.46 million, a price-to-earnings ratio of -0.21 and a beta of 1.79. Cibus has a 52-week low of $2.86 and a 52-week high of $23.18.

Institutional Investors Weigh In On Cibus

Hedge funds have recently modified their holdings of the business. SG Americas Securities LLC bought a new position in Cibus in the third quarter worth $33,000. FineMark National Bank & Trust lifted its holdings in shares of Cibus by 24.3% during the second quarter. FineMark National Bank & Trust now owns 20,488 shares of the company’s stock valued at $202,000 after acquiring an additional 4,000 shares during the period. Squarepoint Ops LLC bought a new position in shares of Cibus during the second quarter valued at $214,000. Rhumbline Advisers acquired a new stake in shares of Cibus in the second quarter valued at $221,000. Finally, Swan Global Investments LLC acquired a new stake in shares of Cibus in the third quarter valued at $115,000. 33.81% of the stock is owned by institutional investors.

About Cibus

Cibus, Inc, a agricultural biotechnology company, develops and licenses plant traits to seed companies for royalties. The company primarily focus on trait productivity in two areas, including productivity traits that enable farmers to have higher yields and reduce the use of the crop protection chemicals and fertilizers; and sustainable ingredients that enable corporations to replace ingredients that are fossil fuel based or whose production results in increased greenhouse gases.